UNCY Unicycive: ערך חשבונאי למניה

Unicycive Therapeutics combines powerful scientific potential with the capacity for the mass production of affordable renal medications. Checking the book value of the company's shares on GURU.Markets, we see that 1.92 becomes the new value of this metric. Currently, the biotech ecosystem is focusing on the drug Oxylanum, which is awaiting FDA approval, maintaining its patient base through convenient dosages.

Unicycive Therapeutics (UNCY) reliance on external GMP facilities minimizes capital expenditures, shifting the focus toward intangible assets. The trend in final book value per share reflects the equity portion per security, allowing investors to assess real asset density and the level of bankruptcy protection through the lens of net asset value.